Onco-Innovations' Licensed Technology Shows Promise in Enhancing Chemotherapy Effectiveness by Overcoming Cancer Cell Resistance and Inhibiting Cancer Cell Repair
VANCOUVER, BC / ACCESS Newswire / January 30, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ('Onco' or the 'Company') is pleased to provide information on its licensed technology of a new class of PNKP (Polynucleotide Kinase 3'-Phosphatase) inhibitors (the 'Technology') which has demonstrated, in a study[1], the ability to enhance the efficacy of cancer killing inhibitors, known as topoisomerase I poisons, in certain cancer treatments. By enhancing cancer cells' sensitivity to topoisomerase I poisons, this breakthrough technology shows the potential, through further research and development, to one day improve patient outcomes across certain cancers by making chemotherapy more effective while also directly inhibiting cancer cells' ability to repair their own DNA. This innovation holds the potential to become a promising and important part of the expanding global cancer therapy market.[2]
'Our Technology aims to address a critical challenge, which is to overcome drug resistance in cancer treatment and stop cancer cells from being able to repair themselves. With the goal of enhancing the sensitivity of cancer cells to existing therapies, we believe we can continue moving towards improving patient outcomes. That is what drives us in our journey to transform cancer care as we position Onco-Innovations as a key player in a rapidly growing multi-billion-dollar market,' said Thomas O'Shaughnessy, CEO of the Company.
Topoisomerase I poisons work by disrupting the DNA replication process in cells, a critical step for cell division. Normally, the enzyme Topoisomerase enzymes cleave the hypercoiled segments of DNA, relax the DNA strands, and then reattach the cleaved ends, thereby allowing the transcription to progress.[3] When topoisomerase I poisons are introduced, they prevent the enzyme from reattaching cut ends, leading to breaks in the DNA that can cause cancer cells to die.[4] However, the challenge with topoisomerase I poisons is that cancer cells can sometimes activate their DNA repair mechanisms to fix the breaks caused by these drugs, which can reduce the overall effectiveness of the treatment. [5] This ability to repair the damage allows some cancer cells to survive and continue proliferating despite the therapy, leading to potential treatment resistance.[6]
Human polynucleotide kinase-phosphatase (PNKP) has been recognized as a crucial enzyme in the DNA repair process, particularly following damage caused by ionizing radiation (IR) or topoisomerase I poisons in multiple cancer types, including colorectal cancer (CRC). By targeting PNKP to make cancer cells more sensitive to these drugs, Onco-Innovations' Technology has shown promise in enhancing the effectiveness of these treatments, a therapeutic potential validated by various research groups[7]. This innovative approach holds the promise of one day potentially improving outcomes for patients undergoing cancer therapy. Unlike traditional treatments that often face limitations in targeting resistant cancer cell populations, the Technology has been shown in a study[8] to directly inhibit cancer cells' ability to repair their own DNA, a critical factor in their survival.
Conventional treatments frequently fail for several reasons. Radiation therapy, for instance, struggles with poor target definition and can be less effective in tumors that lack sufficient oxygen (hypoxia). Chemotherapy, meanwhile, often faces challenges related to poor drug delivery or the body's inability to properly metabolize the treatment. In both cases, cancer cells are notoriously adept at evading destruction, whether by developing resistance, down-regulating pathways that promote cell death, or through the high sensitivity of normal tissues to these therapies. The ability of cancer cells to repair DNA damage inflicted by these treatments is one of the key factors that allows them to survive and continue proliferating despite ongoing therapy.[9]
Onco's novel Technology holds promise in treating tumors that have previously shown resistance to conventional therapies, potentially offering a more effective solution for patients who have exhausted existing options. Moreover, by selectively targeting cancer cells' repair systems, the Technology could potentially minimize the harmful effects on normal tissues, with the goal of further improving patient outcomes. We note that the Company's plans with respect to the Technology include pursuing U.S. Federal Drug Administration Phase I trials, wit the aim of commencing the trials this year.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented groundbreaking technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
'Thomas O'Shaughnessy'
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Technology, the Company's ability to submit and complete U.S. FDA trials, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Technology, the failure to complete U.S. FDA clinical trials, the failure to receive regulatory approval in respect of the Technology, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
[1] Front. Oncol., 22 December 2021 Sec. Cancer Molecular Targets and Therapeutics Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.772920
[3] 'All tangled up: how cells direct, manage and exploit topoisomerase function' in Nat Rev Mol Cell Biol. 2011 Nov 23;12(12):827-41. doi: 10.1038/nrm3228. See Section Type IA: single-stranded 'strand-passage' enzymes.
[4] Managing DNA's topology to keep genes active. Center for Cancer Research, National Cancer Institute. 2017. Available at: .
[6] " Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.' Journal of clinical oncology: official journal of the American Society of Clinical Oncology vol. 26,17 (2008): 2839-45.
[7]Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage' in Frontiers in Oncology. Volume 11, 2021 Dec 22 11:772920
[8] Front. Oncol., 22 December 2021 Sec. Cancer Molecular Targets and Therapeutics Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.772920
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
10 minutes ago
- Associated Press
BlackBerry to Announce First Quarter Fiscal Year 2026 Results on June 24, 2025
WATERLOO, ON / ACCESS Newswire / June 10, 2025 / BlackBerry Limited (NYSE:BB)(TSX:BB) will report results for the first quarter fiscal year 2026 at 5:30 p.m. ET on Tuesday, June 24, 2025. The conference call can be accessed as a live webcast using the following link ( here ) or through the events section of the Company's investor webpage ( ) or by dialing toll free +1 (844) 763-8275 and entering Elite Entry Number 52549. A replay of the conference call will be available at approximately 8:30 p.m. ET on June 24, 2025, using the same webcast link (here ) or by dialing toll free +1 (877) 481-4010 and entering Replay Access Code 52549. The following table gives target dates for quarterly earnings announcements for the remainder of fiscal year 2026: * The dates given are for planning purposes only and a press release confirming the earnings date will be issued approximately 2 weeks before. About BlackBerry BlackBerry (NYSE:BB)(TSX:BB) provides enterprises and governments the intelligent software and services that power the world around us. Based in Waterloo, Ontario, the company's high-performance foundational software enables major automakers and industrial giants alike to unlock transformative applications, drive new revenue streams and launch innovative business models, all without sacrificing safety, security, and reliability. With a deep heritage in Secure Communications, BlackBerry delivers operational resiliency with a comprehensive, highly secure, and extensively certified portfolio for mobile fortification, mission-critical communications, and critical events management. For more information, visit and follow @BlackBerry. ### Investor Contact: BlackBerry Investor Relations +1 (519) 888-7465 [email protected] Media Contact: BlackBerry Media Relations +1 (519) 597-7273 [email protected] SOURCE: BlackBerry press release
Yahoo
31 minutes ago
- Yahoo
Pluto Ventures Announces Appointment of Tyler Tian as Director
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2025) - Pluto Ventures Inc. (CSE: PLTO) ("PLTO" or the "Company") is pleased to announce the appointment of Tyler Tian as the director of the Company, effective immediately. Mr. Tyler Tian graduated from the British Columbia Institute of Technology with a degree in Mining and Mineral Resource Engineering. He also holds a Master of Engineering Management degree from the University of Ottawa and a second undergraduate degree in Environmental Engineering. Mr. Tian is a licensed Professional Engineer ( in British Columbia. He has participated in a range of mineral exploration projects across Canada, including in British Columbia, Ontario, the Yukon, and Québec. Through Fargo Exploration Ltd., a BC-based private company, he provides geological consulting services to both public and private sector clients. The Company also announces that Queenie Kuang has resigned as the director and chair of the audit committee effective May 31, 2025. The Board extends its gratitude to Ms. Kuang for her contributions and wishes her well in her future endeavors. About the Company Pluto Ventures Inc., headquartered in Vancouver, BC, Canada, is a mineral exploration company engaged in the acquisition, exploration, and development of mineral properties. The Company's current principal project is the Dardanelle Project, which covers an area of 1,434 hectares located 23 kilometers east of Terrace, British Columbia. ON BEHALF OF THE BOARD OF DIRECTORS "Lawrence Tsang" Lawrence Tsang, President and Chief Executive Officer For further information, please contact the Company at: (604) 688-9588 Cautionary Statement Regarding "Forward-Looking" Information This news release includes certain statements that may be deemed "forward-looking statements". All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements in this news release include statements related to the Proposed Transaction, satisfaction of the conditions precedent to the Proposed Transaction, and the acquisition of the Union Bay Property and related matters. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward- looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Volta Options Springer Rare Earth and Gallium Deposit
Toronto, Ontario--(Newsfile Corp. - June 10, 2025) - Volta Metals Ltd. (CSE: VLTA) (FSE: D0W) ("Volta" or the "Company") is pleased to announce that, further to the Company's press release issued on February 27, 2025, the Company has entered into a definitive option agreement dated June 9, 2025 (the "Definitive Agreement") with RZJ Capital Management, LLC (the "Vendor") to acquire an initial 80% interest (the "First Option") and up to a 100% interest (the "Second Option") in the Lavergne-Springer ("Springer") Rare Earth and Gallium project (the "Transaction") located 80km east of Sudbury, Ontario, Canada (the "Project" or "Property") (Figure 1), subject to certain encumbrances as noted below. The Project consists of 5,000 hectares of patented and non-patented claims and contains a historic NI 43-101 mineral resource for Total Rare Earth Oxides ("TREO") of 4.167mt at 1.073% TREO indicated and 12.73mt at 1.119% TREO in the inferred resource category at a cut-off of 0.9%. Mineralization starts at surface, the deposit remains open for expansion, and the large Property is underexplored for REE-Ga mineralization. Project Highlights Advanced Rare Earth Project (REE) with associated high-grade Light REE and gallium near Sturgeon Falls, Ontario. Excellent infrastructure with paved road access (1 hour from the Sudbury Mining Hub), rail and hydroelectric power servicing the Property (Figure 2). Multiple wide, shallow intercepts of +100m at >1% TREO, including one of the final drill holes finishing in 12m at 5% TREO with no subsequent follow-up drilling. Consistent elevated gallium intercepts ranging from 57 to 120 g/t over thick intervals, including 87.5m at 76.4 g/t and 88m at 62 g/t gallium. Positive initial laboratory scale metallurgical test work to produce an upgraded Light Rare Earth concentrate. 5,000 Ha property with patented claims covering the known deposit and unpatented claims covering potential extensions to the east and west. The Springer Deposit Tetra Tech Wardrop of Toronto completed the (historic) resource estimate in May 2012 for Rare Earth Metals Inc., which was a junior exploration company listed on the TSX Venture Exchange (Table 1 and 2). The mineral resource estimate was completed in accordance with CIM Best Practices and Disclosure guidelines in accordance with NI 43-101 at that time, and Volta has no reason to believe that the mineral resources estimate contained is not relevant or reliable as of the date hereof (Figure 1). Figure 1. Springer REE Deposit (blue), with Gallium (brown) view an enhanced version of this graphic, please visit: Table 1. Indicated Resource Estimate for the Springer Deposit TREO% Cut-off Density Tonnes ('000) LREO% HREO%* TREO% HREO:LREO Ratio ThO2% 1.30 2.59 759 1.363 0.080 1.443 6 0.018 1.20 2.60 1,384 1.280 0.074 1.353 5 0.017 1.10 2.60 2,124 1.209 0.072 1.281 6 0.017 1.00 2.60 3,028 1.143 0.069 1.212 6 0.016 0.90 2.60 4,167 1.073 0.066 1.139 6 0.016 0.80 2.60 6,022 0.987 0.062 1.049 6 0.015 0.70 2.61 8,249 0.910 0.058 0.967 6 0.014 0.60 2.61 10,719 0.840 0.054 0.894 6 0.013 *: Includes yttrium oxide (Y2O3) Table 2. Inferred Resource Estimate for the Springer Deposit TREO% Cut-off Density Tonnes ('000) LREO% HREO%* TREO% HREO:LREO Ratio ThO2% 1.30 2.65 2,805 1.482 0.053 1.535 3 0.010 1.20 2.65 4,405 1.378 0.053 1.431 4 0.010 1.10 2.65 6,531 1.285 0.053 1.337 4 0.011 1.00 2.64 9,433 1.196 0.052 1.249 4 0.011 0.90 2.65 12,732 1.119 0.051 1.170 4 0.011 0.80 2.65 18,274 1.024 0.048 1.072 5 0.010 0.70 2.65 25,917 0.931 0.045 0.976 5 0.009 0.60 2.65 38,876 0.825 0.041 0.866 5 0.008 *: Includes yttrium oxide (Y2O3) The mineral resource, based on 22 diamond drill holes, was estimated by the Ordinary Kriging interpolation method on uncapped grades for all 15 Rare Earth Oxides ("REO"). The TREO% is a sum of the 15 individual interpolations of the REOs. The resource estimate was prepared using a single interpreted domain using a grade shell of 0.31 TREO%. A cut-off grade of 0.9 TREO% was chosen for the deposit resource estimate based on comparable deposits at the time (Table 1 and Table 2). No recoveries have been applied to the interpolated estimates. Volta is unaware of any other work having been completed on the Project since the 2012 mineral resource estimate. The resource estimate presented for the Springer project is historic in nature. Volta's qualified person has not completed sufficient work to confirm the results of the historical resource. Volta is not treating this as a current mineral resource but is considering it relevant as a guide to future exploration and is included for reference purposes only. Volta will require further drilling to verify the historic estimate as current mineral resources. Figure 2. Location of Springer Rare Earth Project in OntarioTo view an enhanced version of this graphic, please visit: Infrastructure The Project is located 8 km outside of Sturgeon Falls, Ontario, near the Trans-Canada Highway, the Sturgeon Falls Power Station, and the Railway Station. The Crystal Falls Power Station is located 7 km east of the project site, and power lines and paved roads run across the Property (Figure 3). The Project site is accessible from Sudbury and North Bay and is workable year-round. Figure 3. (a) Sturgeon Falls Power Dam and (b) Crystal Falls Power Lines on PropertyTo view an enhanced version of this graphic, please visit: Gallium Intercepts Historic drilling also returned thick intercepts of high-grade Gallium (Table 3). For reference, the Codero Deposit in Nevada is one of the largest unmined primary gallium deposits in North America, with a reported resource of 15M tonnes at 47.7ppm, with a cut-off grade at 30ppm ( Gallium is a critical component in the semiconductors, telecommunications, and renewable energy sectors and may also be considered as a possible heat exchange medium in nuclear reactors. Canada and the U.S. rely on gallium for telecommunications, defense, and green energy. Gallium is also used in semiconductors, AI circuitry, radar and microchips. On December 3, 2024, China announced an immediate ban on the export of multiple critical metals, including gallium, exacerbating supply chain challenges. China currently accounts for 98% of worldwide primary low-purity gallium production. Examination of the drill database and 3D modelling by the Company as part of its due diligence suggests that the Springer deposit may contain a significant gallium resource. There has been no petrographic or metallurgical testwork completed on the gallium; consequently, it is currently unknown if it is recoverable and/or could form a potentially valuable by-product. Future work will seek to address this. The Company intends to drill and update the 2012 resource estimate in the upcoming exploration season. Table 3. Gallium & REE Composite Assays from 2012 Drilling Borehole From (m) To (m) Interval (m) Ga2O (g/t) Nb2O5 % La2O3 (g/t) CeO2 (g/t) Pr6O11 (g/t) Sm2O3 (g/t) Nd2O3 (g/t) LREO (g/t) HREO (g/t) SL-11-01 132.4 219.9 87.5 102.7 0.09 4,027 7,296 724 256 2,312 14,673 868 SL-11-02 213.8 277.0 63.2 96.2 0.05 3,420 5,106 739 235 1,988 12,858 714 SL-11-03 86.6 94.1 7.6 80.1 0.06 3,950 6,686 606 156 1,753 13,182 216 SL-11-03 101.4 113.4 12.0 102.2 0.07 5,373 9,376 902 279 2,662 18,654 455 SL-11-03 135.9 153.2 17.3 97.2 0.05 5,451 8,909 828 959 2,326 17,760 266 SL-11-03 178.6 189.1 9.0 77.7 0.07 6,988 11,686 1,122 347 3,369 23,587 508 SL-11-03 209.9 223.9 14.0 95.8 0.03 10,341 18,006 1,715 706 5,463 36,390 1,051 SL-11-03 247.9 252.9 5.0 97.3 0.03 11,805 19,517 1,779 672 5,402 39,328 924 SL-12-08 19.0 37.0 18.0 83.3 - 5,653 9,722 967 346 3,078 19,838 649 SL-12-08 37.0 125.0 88.0 83.3 - 3,514 6,537 693 302 2,352 13,463 633 SL-12-09 66.0 102.0 36.0 77.0 - 2,847 6,378 767 397 2,958 13,471 677 SL-12-18 94.7 101.7 7.0 86.4 - 2,676 5,842 702 509 2,789 12,629 403 Transaction Terms The patented claims that comprise the Property are subject to an underlying option agreement (the "Underlying Agreement") between the Vendor, as optionee and certain optionors (the "Underlying Optionors"). The Company has the right to become the optionee under the Underlying Agreement in the event of a default by the Vendor under such agreement. In order to earn an 80% interest in the Property, Volta must: On the closing date of the Definitive Agreement, issue an aggregate of 10,000,000 Common Shares to the Vendor (the "Closing Shares"), make a cash payment of $100,000 to the Vendor, and an aggregate cash payment of $220,400 to the Underlying Optionors; On or before the first anniversary of the execution date of the Definitive Agreement (the "Execution Date") issue an aggregate of 2,500,000 Common Shares to the Vendor (the "First Anniversary Shares"), and make an aggregate cash payment of $266,000 to the Underlying Optionors; and On or before the second anniversary of the Execution Date, issue an aggregate of 2,500,000 Common Shares to the Vendor (the "Second Anniversary Shares"), make an aggregate cash payment of $266,000 to the Underlying Optionors, a cash payment of $160,000 to the Vendor, and an additional cash payment of $76,000 to the Underlying Optionors. Upon exercise of the First Option, the Company will grant the Vendor a 2.0% net smelter returns royalty on the unpatented claims which comprised the Property (the "Granted Royalty"), of which of which 1% of the Granted Royalty may be bought back for $1,000,000 and assume the obligation to pay 80% of the existing 2.85% net smelter returns royalty on the patented claims which comprise the Property (the "Existing Royalty"), of which 0.95% of the Existing Royalty may be bought back for $950,000. The patented claims which comprise the Property are subject to the rights of a certain owner of a 5% interest in such claims (the "Remaining Holder"), accordingly, the First Option is with respect to an 80% interest to 95% of the patented claims and 100% of the unpatented claims. Pursuant to the Definitive Agreement, the Company may acquire the remaining 20% interest (the "Remaining Interest") until the date that is twelve months following the completion of a feasibility study on the Property by paying the Vendor the fair market value of the Remaining Interest at the time of exercise. Closing of the Transaction is subject to certain terms and conditions, including but not limited to the approval of the Canadian Securities Exchange. All Common Shares issued pursuant to the Transaction will be subject to a hold period of four months and one day from the date of issuance. In addition, certain of the Closing Shares shall be subject to the following trading restrictions: 2,500,000 Closing Shares shall not be tradeable until after the date that is six (6) months from the Closing Date, 2,500,000 Closing Shares shall not be tradeable until after the date that is twelve (12) months from the Closing Date and 2,500,000 Closing Shares shall not be tradeable until after the date that is eighteen (18) months from the Closing Date. Qualified Person The technical content of this news release has been reviewed and approved by Andrew Tims, who is an independent Qualified Person (QP) as defined in National Instrument 43-101, Standards of Disclosure for Mineral Projects. The QP and the Company have not completed sufficient work to verify the historical information on the Project. For more information about the Company, view Volta's website at ABOUT VOLTA METALS LTD. Volta Metals Ltd. (CSE: VLTA) (FSE: D0W) is a mineral exploration company based in Toronto, Ontario, focused on REE, gallium, lithium, cesium, and tantalum. It has optioned and is currently exploring a critical minerals portfolio of REE, gallium, lithium, cesium, and tantalum projects in northwestern Ontario, considered one of the world's most prolific, emerging hard-rock lithium districts. To learn more about Volta and its Aki Project and its recently acquired Springer Project, please visit ON BEHALF OF THE BOARD For further information, contact: Kerem Usenmez, President & CEOTel: 416.919.9060Email: info@ Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking statements relating to product development, plans, strategies, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking information in this news release includes, but is not limited to, the timing and anticipated completion of the Transaction, the entering into of the Definitive Agreement, regulatory approvals for the Transaction, that the Transaction is transformative for Volta, statements regarding the Transaction, the ability to complete the Transaction on the terms provided herein or at all, the receipt of all necessary approvals, the Company's planned exploration activities and the Company's aim to prevent and minimize impacts on the First Nations through a variety of mitigation measures and offsetting benefits. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include: that the Company may not close the Transaction on the terms contemplated or at all, that due diligence with respect to the Transaction will not be favourable, that the Transaction may not be consummated, that the rights of the Remaining Holder will impede the Company's ability to conduct exploration activities on, and potential develop, the Property, the risks detailed from time to time in the filings made by the Company with securities regulators; the fact that Volta's interests in the Property are options only and there are no guarantee that such interest, if earned, will be certain; the future prices and demand for lithium; and delays or the inability of the Company to obtain any necessary approvals, permits and authorizations required to carry out its business plans. The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required by law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
